EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study

Matteo D'Addona, Luca Pezzullo, Lorenzo Settembre, Emilia Vaccaro, Roberto Guariglia, Bianca Serio, Laura Mettivier, Andrea Gigantiello, Giovanni Signorile, Angela Bertolini, Francesca Picone, Bianca Cuffa und 2 weitere

Journal of Cancer Research and Clinical Oncology · 2025

DOI: 10.1007/s00432-025-06351-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Matteo D'Addona und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081, Baronissi, Italy. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Virus Activation, Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Salerno.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab and obinutuzumab, anti-CD20 monoclonal antibodies, are widely employed for treatment of follicular lymphoma (FL) by targeting both neoplastic and normal CD20-expressing B lymphocytes, consequently inducing immunosuppression. In this condition, viral reactivations are common and represent a major cause of morbidity and mortality. In this single-center two-arm observational real-life study, we evaluated incidence, immunological and serological status, and clinical outcomes of cytomegalovirus (CMV) reactivation in FL patients treated with bendamustine + rituximab (R-BENDA; N = 23) or obinutuzumab (G-BENDA; N = 23). CMV reactivation more frequently occurred in patients treated with R-BENDA compared to G-BENDA ( P = 0.022), and immune kinetics showed significant differences between the two groups, with a deeper and earlier immunosuppression in R-BENDA treated subjects. Moreover, R-BENDA group displayed a significant higher risk of CMV reactivation compared to G-BENDA (hazard ratio, 2.232; 95% confidence interval 1.107–4.500; P = 0.0249). However, G-BENDA patients tended to have a shorter 5-year overall survival (59% vs. 86.7%, G-BENDA vs. R-BENDA; P = 0.0903). By multivariate analysis, B symptoms were an independent predictor of CMV reactivation, and high baseline SUV as an additional risk factor in R-BENDA patients. In conclusion, anti-CD20 agent could increase the risk of CMV reactivation in FL patients, especially in R-BENDA treated subjects who experienced early and deep immunosuppression. Therefore, close monitoring of clinical and laboratory data may improve outcomes in FL patients by preventing CMV disease, especially in those treated with rituximab who are more prone to viral reactivation. However, larger prospective studies are required to confirm our preliminary results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularVirus ActivationCytomegalovirusCytomegalovirus InfectionsAntineoplastic Combined Chemotherapy ProtocolsHumansRituximabFemaleMaleBendamustine HydrochlorideMiddle AgedAgedAntibodies, Monoclonal, HumanizedIncidenceAdultAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

Anti-CD20 monoclonal antibodiesCytomegalovirusFollicular lymphomasImmune reconstitutionViral reactivation

Substanzen

obinutuzumabRituximabBendamustine HydrochlorideAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081, Baronissi, Italy.
  • Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
  • Molecular Biology Section, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84131, Salerno, Italy.
  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081, Baronissi, Italy. cselleri@unisa.it.
  • Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy. cselleri@unisa.it.

Förderung

  • Università degli Studi di Salerno

Zitieren

APA

D'Addona, M., Pezzullo, L., Settembre, L., Vaccaro, E., Guariglia, R., Serio, B., Mettivier, L., Gigantiello, A., Signorile, G., Bertolini, A., Picone, F., Cuffa, B., Giudice, V., & Selleri, C. (2025). Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06351-2

Vancouver

D'Addona M, Pezzullo L, Settembre L, Vaccaro E, Guariglia R, Serio B, et al. Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06351-2

BibTeX
@article{DAddona2025,
  author = {D'Addona, Matteo and Pezzullo, Luca and Settembre, Lorenzo and Vaccaro, Emilia and Guariglia, Roberto and Serio, Bianca and Mettivier, Laura and Gigantiello, Andrea and Signorile, Giovanni and Bertolini, Angela and Picone, Francesca and Cuffa, Bianca and Giudice, Valentina and Selleri, Carmine},
  title = {Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab–bendamustine in follicular lymphoma: a single-center case series study},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06351-2}
}
Kostenlos starten →